European Society for Medical Oncology (ESMO)

The European Society for Medical Oncology (ESMO) is the leading professional organisation for medical oncology. With more than 25,000 members representing oncology professionals from over 150 countries worldwide, ESMO was founded in 1975.
Circulating Tumor Cell Counts May Have Prognostic Value in Determining First-Line Therapy in HR+/HER2– Metastatic Breast Cancer
ESMO 2016
In patients with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) metastatic breast cancer, the decision to treat first with hormone therapy or chemotherapy can be made at the discretion of the attending oncologist, or by taking into account the number of circulating tumor cells. This phase 3 study compares the outcome of these 2 methods. Read More ›
Claim Data Reveal Treatment and Toxicity Patterns Associated with Everolimus Use
ESMO 2016
Everolimus, an inhibitor of mammalian target of rapamycin, is approved for use in the United States and European Union in combination with exemestane (an aromatase inhibitor) for the treatment of postmenopausal women with advanced estrogen receptor–positive/human epidermal growth factor receptor 2–negative breast cancer. This retrospective study evaluates the patterns of care and complications associated with this treatment over a 5-year period (2009-2014). Read More ›
Conversion of Biomarkers Between Primary Breast Cancer Tumor and Relapse May Have Prognostic Value
ESMO 2016
In a retrospective study of 45 breast cancer patients, the differential expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 is evaluated in primary and relapsed tumors. The conversion rate of these biomarkers and their prognostic relevance are assessed. Read More ›
Improved Sensitivity to Endocrine Therapy Following Treatment with Eribulin Mesylate
ESMO 2016
Eribulin mesylate is an inhibitor of microtubule dynamics that may play a role in reducing the abnormality of the tumor microenvironment (ie, increasing oxygenation). As hypoxic conditions may contribute to drug resistance, it is hypothesized that eribulin may enhance the efficacy of other therapies. In this study, the effects of eribulin on 2 endocrine therapies were evaluated. Read More ›
Exploring the Relationship Between Progression-Free Survival and Overall Survival in Breast Cancer Patients Treated with Fulvestrant or Anastrozole
ESMO 2016
Progression-free survival (PFS) is often used as a surrogate for overall survival (OS) due to the challenges of measuring OS in relatively short-term trials, and is a practice that has been supported by previous analyses of breast cancer data. This analysis further examines the relationship between PFS and OS in advanced breast cancer. Read More ›

Page 7 of 9

© Amplity Health. All Rights Reserved. Privacy Policy